VEGFB and metabolic dysfunction-associated steatotic liver disease: On the other hand, the VEGFB gene was downregulated; this vascular endothelial growth factor controls tissue lipid accumulation, and its inhibition reduces hepatic steatosis and non-alcoholic fatty liver disease in mice (Falkevall et al. 2023).